Skip to Content

Tengion Inc TNGNQ

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TNGNQ is trading at a 384% premium.
Price
$0.00
Fair Value
$3.13
Uncertainty
Extreme
1-Star Price
$7.74
5-Star Price
Economic Moat
Gnfkvt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNGNQ is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.02
Market Cap
$40.25
Volume/Avg
250 / 250

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
27

Valuation

Metric
TNGNQ
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
TNGNQ

Financial Strength

Metric
TNGNQ
Quick Ratio
0.10
Current Ratio
0.10
Interest Coverage
−7.24
Quick Ratio
TNGNQ

Profitability

Metric
TNGNQ
Return on Assets (Normalized)
−125.62%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
TNGNQ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
ZxxtnrbrxTbd$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
FybccsstwFlxfqkr$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
SrbkbgtfVfjgczx$121.2 Bil
Moderna Inc
MRNA
GnnkrytnSgqz$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
MqyxgbfcnJklwkp$33.0 Bil
argenx SE ADR
ARGX
NrfhttrqHkzb$27.9 Bil
BioNTech SE ADR
BNTX
DrvlsnlhMlq$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
MczqmljzGtwgnc$16.1 Bil
United Therapeutics Corp
UTHR
YcbcxczhMtqhw$14.3 Bil
Incyte Corp
INCY
MfzxzjmsFtcrz$12.5 Bil

Sponsor Center